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Key Points 
 This is the first systematic review for liver disease in AATD, and includes outcomes for 
1564 children and 626 adults with AATD.  
 Non-invasive measurement of liver fibrosis for those with AATD may help to identify those 
with early liver disease who will benefit from emerging therapies. 
 AATD can have an aggressive course in children, with 16% developing liver failure and 
requiring transplantation. Similarly, 14.7% of adults undergo liver transplantation. 
 Although phase II trials are anticipated, liver transplantation remains the only treatment 
for AATD-related liver disease, and has favorable outcomes compared with other 
indications.  
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SUMMARY 
Background  
Alpha-1 antitrypsin deficiency (AATD) is estimated to affect 3 million people worldwide. It 
causes liver disease in a proportion of carriers of the PiS and PiZ allele due to the formation and 
retention of polymers within the endoplasmic reticulum of hepatocytes. The reason for this 
selective penetrance is not known. Although clinical trials are underway, liver transplantation is 
the only effective treatment for liver disease due to AATD.  
Aims  
Through systematic review, we report the prevalence and natural history of liver disease among 
individuals with AATD, and assess the outcomes of liver transplantation.  
Methods  
A comprehensive search was conducted across multiple databases. Two independent authors 
selected the articles and assessed bias using the Newcastle-Ottawa Scale. Data was pooled for 
analysis where comparable outcomes were reported.  
Results  
35 studies were identified related to disease progression and 12 for the treatment of AATD. 7% 
of children were reported to develop liver cirrhosis, with 16.5% of individuals presenting in 
childhood requiring liver transplantation. Of those surviving to adulthood, 10.5% had liver 
cirrhosis and 14.7% required transplantation. Liver transplantation was the only effective 
treatment reported and outcomes compare favourably to other indications, with five-year 
survival reported as over 90% in children and over 80% in adults.  
Discussion  
The clinical course of liver disease in individuals with AATD remains poorly understood, but 
affects about 10% of those with AATD. More research is required to identify those patients at 
risk of developing liver disease at an early stage, and to provide alternative treatments to liver 
transplantation. 
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INTRODUCTION 
Alpha-1-antitrypsin deficiency (AATD) is estimated to affect 3 million people worldwide (1), 
with patients typically developing lower zone emphysema at a relatively young age.  Point 
mutations lead to altered folding during AT biogenesis, and misfolded proteins form polymers 
that are retained within the endoplasmic reticulum of hepatocytes, rather than being 
systemically secreted (PMID: 17464974).  In the lung, lack of AT permits uninhibited proteolytic 
damage to the connective tissue matrix, leading to emphysema in approximately 75% of PiZZ 
patients (5).  Liver disease occurs due to aggregation of AT polymers within the endoplasmic 
reticulum (ER) of liver cells, which form periodic acid-Schiff positive inclusions, a hallmark 
biopsy feature in AATD-related liver disease (8). Hepatocyte injury is believed to be related to 
ER stress, mitochondrial dysfunction, and triggering of autophagy, although the true 
pathophysiology is yet to be fully understood (PMID: 21421920). There is considerable 
variability of phenotypic expression in both liver and lung disease (3), which is believed to 
reflect genetic (2) and environmental modifiers (4). Cigarette smoking has been demonstrated 
to be the greatest predictor of lung function impairment in AATD cohorts (5) and smoking 
cessation is the most effective treatment strategy (6).  
In children AATD-related liver disease may present only transiently, being diagnosed after 
investigation for prolonged neonatal jaundice, whilst in others disease may persist, progressing 
to fibrosis and cirrhosis requiring childhood liver transplantation (9). In adults liver disease has 
been reported in several cohorts or case series, with prevalence varying depending on the 
modality used to diagnose disease. In one study, clinical signs or symptoms suggestive of liver 
disease were reported in up to 63% of homozygous patients, (10) whereas other studies 
describe abnormalities of liver enzymes (e.g. ALT) in less than 10% of adult patients (11, 12).  
Another paper published in 1986 reported biopsy-defined fibrosis/cirrhosis in 17.5% of 
patients (7).  
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Serum tests have also been investigated as possible predictors of significant liver disease with 
mixed results (11-14).  Measurement of GGT may be of benefit (15) but is possibly confounded 
by its probable relation to oxidative lung injury and airflow obstruction (16).  Tests intended to 
detect liver fibrosis are currently likely to be the most useful, such as the serum enhanced liver 
fibrosis (ELF) test (17) and/or transient elastography (which has a sensitivity of 71% and 
specificity of 91% using a cut off of 8KPa to detect advanced fibrosis) (18), but more data in this 
cohort is needed.  
The heterogeneity of liver disease in AATD implies that like lung disease, intrinsic factors such 
as genetics interact with environmental factors to determine clinical phenotype. Some studies 
have shown that heterozygosity for the Z allele (e.g. PiMZ) confers an increased risk of fibrosis 
or cirrhosis compared to the general population (16,17) but it seems likely that co-factors such 
as alcohol consumption and non-alcoholic steatohepatitis (NASH) play a greater role in 
heterozygous forms of AATD (19, 20).   
In this systematic review the aims were to describe liver disease progression in AATD and 
assess the clinical effectiveness of liver transplantation. 
METHODS 
Standard systematic review methodology aimed at minimising bias was employed. The main 
protocol was registered with PROSPERO (CRD42016040134).  
Searches 
The search strategy is shared in the supplementary material; it was initially broad and included 
the terms: alpha 1-antitrypsin deficiency; disease monitoring; disease progression; humans; 
liver; mortality; incidence. The following sources were searched from inception, with no 
language restrictions or study design filters: Bibliographic databases (MEDLINE, MEDLINE In 
Process and EMBASE via Ovid, CINAHL via EBSCO, Cochrane Library (CDSR, DARE, HTA, NHS 
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EED and CENTRAL databases), Science Citation Index (ISI); current controlled trials 
metaRegister, ISRCTN database, UKCRN, WHO ICTRP Portal and ClinicalTrials.gov; specialist 
abstract and conference proceeding resources (British Library’s ZETOC and ISI Proceedings). In 
addition we checked citation lists of included studies and relevant reviews and made contact 
with study authors and researchers of ongoing trials where appropriate to do so. A combination 
of text words and index terms relating to AATD, liver fibrosis and liver cirrhosis were used, and 
results then entered into electronic databases to facilitate record keeping, duplicate removal, 
study selection and document writing.  
Study selection criteria 
Studies eligible for inclusion contained children or adults with AATD, as defined by AAT level 
and genotype (e.g. PiZZ, PiSZ). Some studies included small numbers of individuals with non-
polymerogenic forms of AATD, and were retained as outcomes could not be distinguished 
according to genotype. Systematic reviews and primary study designs that included individuals 
with liver disease of non-AATD aetiology (e.g. “jaundice in neonates”) were eligible if they 
assessed progression or treatment in ≥10 AATD patients. Studies which consisted solely of 
patients heterozygous for AATD were excluded. 
Interventions eligible for inclusion were any treatment said to be for liver disease, and the 
comparator was usual care. In the case of searches for manuscripts describing progression of 
liver disease a comparator was not relevant. Outcomes sought for the treatment review 
included mortality, graft survival, and quality of life.  Where studies reported outcomes in AATD 
and non-AATD patients we specifically sought comparisons of the treatment effect between the 
two groups.  Outcomes of relevance for the progression review included mortality, liver 
transplantation, presence of chronic liver disease, and incidence of HCC.   
 
Review methodology, data extraction and assessment of bias 
Studies were reviewed independently by two reviewers for relevance. Data from manuscripts 
included after review of the full manuscript was extracted by one reviewer and checked by 
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another. Bias was assessed by one reviewer and checked by another using the Newcastle 
Ottawa scale. 
 
Evidence synthesis 
Narrative synthesis of evidence was undertaken for all included studies. We divided the 
synthesis into sub-groups of childhood and adult disease. Meta-analytic methods could not be 
employed due to heterogeneity of study design and outcomes.  
RESULTS 
The PRISMA flow diagram in Figure 1 demonstrates the inclusion of papers related to prognosis 
and treatment of AATD.  Participant characteristics and outcomes are summarized in tables 1 
and 2 respectively, with a more detailed description of relevant studies shown in tables 3 and 4.   
Of 1191 identified records related to prognosis in AATD, 48 full articles were retrieved and 35 
met the inclusion criteria.  Twenty-eight papers reported the outcomes for individuals with 
AATD presenting in children under the age of 16, and seven reported the outcomes of those 
presenting in adulthood. 
7298 records were identified for the treatment of AATD, thirteen articles were retrieved and 
twelve met inclusion criteria.  Some studies included participants with the heterogeneous 
phenotypes PiMZ and PiMS; these studies were only included where the majority (>90%) of 
participants had polmerogenic AATD phenotypes (i.e. PiZZ, PiSZ).  
 
Risk of bias 
There was a high risk of bias for the majority of the studies (figures 2, 3 and table 6 of the 
appendix).  Nearly all were conducted retrospectively, and participants were often selected 
following clinical presentation with manifestations of AATD.  The quality of reporting and 
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conduct of the included studies was often low, especially among smaller, older studies.  
Participant characteristics were often poorly described, with baseline characteristics such as 
age, sex and ethnicity incompletely defined.  Few studies included an appropriate control and 
for those that did, the composition of the control group varied widely.  Follow-up was often 
incomplete and/or relatively short-term outcomes were reported, so that important outcomes 
such as mortality were not always included.   
 
Prognosis and outcomes in AATD related liver disease 
Children 
Twenty-eight papers reporting the prognosis and outcomes of children diagnosed with AATD 
under the age of 16 were reviewed (Table 3).  A series of six papers reported the outcomes of 
127 Swedish children identified at birth through screening and are recorded only once using 
data from the follow-up study at 16 years (21-26). 
 
Participant characteristics: 
There were a total of 1536 participants; characteristics were extracted from papers where they 
were adequately defined, and are summarised in table 1.  Follow up ranged from 3 months to 27 
years.   
 
Disease prevalence and progression 
Only studies using definitive clinical end-points or requirement for liver transplantation were 
included, and the results are summarised in table 2.  There were no reports of Hepatocellular 
carcinoma (HCC). Mortality was reported in 17 studies but overall mortality could not be 
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reported due to data heterogeneity; mortality ranged from 0% in 10 children with PiZZ who 
presented with neonatal cholestasis followed up until 20 years of age (27), to 25.5% in a cohort 
of 98 participants with PiZZ/PiSZ referred to a tertiary centre with liver disease (28).  Outcomes 
following liver transplantation are discussed in the treatment results section.  
 
Adults 
Seven papers primarily reported the outcomes of adult populations (14, 15, 38-42) (Table 3).  
All studies reported outcomes in adulthood, but in three data was collected from presentation at 
birth until adulthood, whereas in the remaining papers follow-up was from adulthood until a 
maximum age of 68.   
 
Participant characteristics: 
In total there were 626 participants, characteristics are summarized in table 1.  Different 
reporting styles precluded reporting of age for adults. 
 
Disease prevalence and progression: 
Chronic liver disease in adults was adequately defined in five studies (14, 15, 38, 39, 41), and 4 
reported liver transplantation as an outcome; the results are shown in table 2.  Mortality was 
reported in four of the seven adult studies.  As with the paediatric studies, there was significant 
heterogeneity between studies for age, phenotype and length of follow up, so overall mortality 
could not be accurately determined.  One paper reported a liver-related mortality of 2.3% in 44 
PiZZ children and adults presenting with abnormal LFTs after a minimum follow up of 4 
years(14); another study of 160 adults with mixed AATD phenotypes referred to a tertiary 
gastroenterology centre with abnormal LFTs reported a non-liver related mortality of 8% in 
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106 patients with AATD but no clinical signs of liver disease. Of the remaining 54 patients that 
had signs of liver disease, mortality was 22% over 14 years follow-up, 85% of which was liver-
related (41).  However, 38% of these patients were found to be hepatitis C (HCV) carriers, and a 
further 40% have evidence of either current or previous Hepatitis B infection, and 
unsurprisingly viral infection was a risk factor for chronic liver disease in this study (41).   
 
 
 
 
 
 
 
 
 
 
 
Table 1. Basic participant characteristics, paediatric and adult studies.  
Outcomes Number of participants 
Paediatric studies 
Liver transplantation 
Cirrhosis  
Portal hypertension 
Jaundice 
 
95 (16.5%) 
36 (7.5%) 
33 (6.9%) 
9 (1.9%) 
Participant Characteristics Number (%) 
Paediatric studies 
Sex 
Age 
Phenotype 
PiZZ 
PiSZ 
PiMZ 
PiSS/PiMS/PiFS 
Rare variants 
Unknown 
Ethnicity 
Caucasian  
 
 
Male: 223 (36.9%) 
0-18 yrs 
 
1154 (75.1%) 
69 (4.5%) 
28 (1.8%) 
12 (0.7%) 
12 (0.7%) 
261 (17.0%) 
 
97.2% 
Adult studies 
Sex 
Age 
Phenotype 
PiZZ 
PiMZ 
PiSZ 
PiSS/PiMS/PiFS 
Unknown 
Ethnicity (from transplant data) 
Caucasian 
 
 
Male: 270 (53.6%) 
16-75 yrs 
 
345 (55.1%) 
171 (27.3) 
87 (13.9%) 
7 (1.1%) 
16 (2.6%) 
 
93.1% 
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Abnormal LFT/prolonged PT 
HCC 
43 (9.0%) 
0 (0.0%) 
Adult studies 
Liver transplantation 
Cirrhosis  
Portal hypertension 
Jaundice 
Abnormal LFTs 
HCC 
 
46 of 312 (14.7%) 
49 (10.5%) 
16 (3.4%) 
Not reported 
12 (3.6%) 
 
Table 2. Outcomes for children and adults with AATD 
 
Factors associated with development of liver disease 
Although a meta-analysis could not be performed, twelve paediatric and four adult studies 
investigated possible risk factors for the development of liver disease in subjects with AATD.  
 
Children 
In paediatric studies, neonatal hepatitis was believed to be a possible factor for the development 
of subsequent chronic liver disease in the study by Ghishan et al (9), whilst Camarena et al 
reported that 44.6% of those who had neonatal cholestasis died or underwent transplant, 
compared with no requirement for transplant for those that presented later in life (34). In 
contrast, neonatal cholestasis was not found to be a risk factor for progression of liver disease in 
the studies by Nemeth et al (27, 43).  
There are similarly conflicting results for serum markers. Francavilla et al found that in children 
requiring transplantation compared with those that did not, aspartate aminotransferase (AST) 
was significantly higher at presentation (p<0.0001), and when combined with gamma-glutamyl 
transferase (GGT) also higher at 6 months (p<0.001), one year (p<0.0003) and five years 
(p<0.01)(30).  Pferdmenges also found that GGT at presentation was predictive of death or liver 
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transplantation in infants (12). However, serum AST at presentation was not noted to be a 
factor in the study by Filipponi et al, although this was an uncontrolled study of 16 children who 
all underwent liver transplantation (11).   
 
Clinical jaundice and synthetic function have also been investigated as potential prognostic 
factors.  Three studies found that raised bilirubin levels, in the “early stages” of the disease (34), 
or at presentation (12, 35) were a risk factor for future progression (p<0.001 in the study by 
Pferdmenges et al)(12), while another study reported that prolonged jaundice (>6 months) in 
those presenting with neonatal hepatitis was more common in those who went on to require 
liver transplantation (30).  A retrospective study of 16 children referred for liver 
transplantation (11) suggested that recurrence of jaundice in children who present with 
neonatal cholestasis should be regarded as an alarm feature, although it is likely that this 
signifies a deterioration in synthetic function. Of note, the study by Moroz et al found no 
correlation between jaundice and clinical outcomes, and although it included fewer patients 
than the other studies that followed up patients from presentation, no other reason for this 
difference could be identified (44).   
Prolonged international normalized ratio (INR), a marker of synthetic function, was found to be 
a risk factor for  poorer outcomes in the study by Pferdmenges (p<0.001) when measured in 
“early disease,” or at diagnosis in the study by Pfister (p<0.001), with a similar, non-significant 
trend being seen in the study by Volpert (12-14).  The same study by Volpert et al saw a trend 
for lower serum albumin at diagnosis in those that later developed cirrhosis, but the findings 
were not significant, (14) and not replicated in other studies, though for the majority of studies 
serum albumin was used as a marker of severity rather than investigated for prognostic 
purposes.   
 
12 
 
Adults 
In adults, a possible increased risk of chronic liver disease in men was observed in a 
retrospective review of 19 individuals with AATD and liver disease (40), and male gender was a 
risk factor (p=0.006) for end-stage liver disease requiring liver transplantation in a 
retrospective follow up of 139 individuals from a US AATD registry with self-reported liver 
disease (42).  In the same study, BMI was also a risk factor (p=0.01) for end-stage liver disease 
requiring liver transplantation (42). Concurrent viral infection (41, 42) and increased alcohol 
intake (39, 42) have not consistently been shown to be risk factors or cofactors for development 
of liver disease in AATD.  
 
Liver biopsy 
12 paediatric and 1 adult study included biopsy findings; and seven studies attempted to 
correlate clinical outcomes with histological features. A summary of biopsy findings is in table 5. 
One retrospective review of 97 children referred to a liver transplant centre found that those 
who developed end-stage liver disease requiring transplantation were more likely to have bile 
duct proliferation (p<0.01), severe fibrosis with bridging septa (p<0.02), and established 
cirrhosis (p<0.04) in biopsies taken at presentation, compared with those who had no 
requirement for transplantation (30).  Hadchouel et al also found that infants with AATD who 
presented with neonatal cholestasis who had bile duct proliferation and portal fibrosis at biopsy 
aged 1-6 months, showed a tendency to develop early cirrhosis and portal hypertension 
compared with those with predominant features of cholestasis, hepatocellular damage, or 
ductular hypoplasia (45). Portal fibrosis was also a risk factor for cirrhosis in children with 
AATD who presented with neonatal cholestasis at <6 months (84.6% vs 26.3%, p<0.01) in the 
study by Nebbia et al (46).   
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Paucity of bile ducts has also been suggested as a factor for poor prognosis (11, 44). In the study 
by Nebbia et al, a higher proportion of children who later developed cirrhosis had this feature at 
biopsy before 6 months of age (31.6% vs 15.8% p=n.s)(11, 46), however, the difference between 
the groups was not significant, and other studies have not replicated these findings (46-48).  
Rujner et al performed a case-control study to investigate whether serum procollagen III levels 
were associated with histological severity of fibrosis in individuals with AATD, but found no 
correlation (49). 
 
Liver Transplantation for AATD-related liver disease 
Although the initial search was designed to encompass all treatments for AATD, the only 
reported therapy in humans was liver transplantation. Twelve retrospective studies discussed 
liver transplantation as a treatment for AATD (see table 4), six studies reported paediatric 
populations (11, 30, 31, 37, 50, 51), and six included both paediatric and adult patients (42, 52-
56).    
 
Children 
The studies included 425 children who underwent liver transplantation for AATD.  Phenotypes 
were reported in 297 children; 95.6% were PiZZ, with the remaining children having PiSZ, PiMZ, 
or unknown phenotypes. 60.5% were male, and median ages ranged from 1.9 and 6 years, with 
a full range of 1-17 years.  Ethnicity was reported in two studies and 254 (97.2%) were 
described as Caucasian. 
Only one study reported the indications for transplantation, with five studies reporting clinical 
features at the time of transplantation.  In 198 participants, ascites was reported in 89 (44.9%), 
jaundice in 48 (24.2%), varices or gastrointestinal bleeding in 78 (39.4%) and encephalopathy 
Comment [ST1]: I could summarise 
this into a table but this may be 
repetitive?  
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in 12 (6.1%). Outcomes following liver transplantation were reported in eight studies and are 
shown in table 4.  Five year survival ranged from 74% from transplant data in the 1980s (51) to 
92% in two studies published since 2000 (30, 52).  Most studies report an excellent quality of 
life in survivors, with no recurrence of AATD in the liver, no pulmonary complications, and 
favourable outcomes compared with other indications for liver transplantation.    
 
Adults 
The studies included up to 656 adults who underwent liver transplantation for AATD.  
Phenotypes were reported in 130 participants, and were PiZZ in 96 (73.8%), and PiSZ in 24 
(18.5%).  74.0% participants were male, and median ages ranged from 34 to 54 years.  93.1% of 
individuals were described as Caucasian. The indications for transplantation were not reported 
in sufficient numbers to draw conclusions.   
Outcomes following liver transplantation are shown in table 4, and were included in four 
studies. Five year survival was 80% in the most recent study published in 2013 (53). Survivors 
report an excellent quality of life, and had no recurrence of liver or lung disease. Only one study 
showed decline in lung function, as measured by FEV1/FVC, in 11 of 17 adults who had pre and 
post-transplant lung function measured; the remaining 6 showed improvement.  A search for 
data on the outcomes of combined liver and lung transplantation for AATD yielded single case-
reports only, although the study by Kemmer et al reported a 100% 8 year survival rate for three 
patients that received separate liver and lung transplantation for AATD-related disease (54).  
DISCUSSION 
 
This is the largest study and only systematic review of AATD-related liver disease, and includes 
over 1000 child and adult participants, drawing data from 47 studies. Despite being a 
recognised cause of liver disease, only 10% of those with polymerogenic AATD phenotypes 
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develop cirrhosis/chronic liver in either childhood or adulthood.  In children, possible 
predictive factors for the development of significant liver disease could be elevated serum AST, 
GGT and prolonged or recurrent jaundice, but it adults it seems likely that additional liver injury 
such as NASH, alcohol or viral infection play a role. 
It is still unknown why some individuals develop AATD related liver disease while others do 
not. The bimodal distribution of clinical presentation in children and adults is a unique 
characteristic of the disease adding another dimension of complexity. In children, serum 
bilirubin level at presentation or the pattern of clinical jaundice may help predict progression of 
liver disease, but no clear pattern or algorithm has been established. Portal fibrosis, and 
possibly bile duct proliferation, observed on liver biopsy at presentation or within the first six 
months of life, also seemed to distinguish those children likely to develop cirrhosis and 
potentially require liver transplantation.  Serological and histological factors such as these 
should be further examined in a prospective, case-control study.   
In adults, male sex and increasing BMI were the only potential risk factors identified for the 
development of end-stage liver disease requiring transplantation. However, non-alcoholic 
steatohepatitis (NASH) is increasingly recognized as a cause of cirrhosis in individuals with the 
metabolic syndrome, and may be responsible for liver disease in those with AATD and raised 
BMI.  Although it seems feasible that cofactors such as alcohol intake or concurrent viral 
infection contribute to the development of liver disease in adults, this was not validated in any 
of the studies.  However, given that such a small proportion of those with AATD develop 
cirrhosis, alternative aetiologies should always be excluded, particularly in individuals with 
non-polymerogenic forms of AATD.  
Only 10% of individuals with AATD develop cirrhosis, and 16.5% of children and 14.7% of 
adults who presented with AATD-related liver disease required transplantation.  However, in 
children it was observed that studies with longer follow up appeared to have better long-term 
outcomes, suggesting that even those presenting with significant liver disease at a young age 
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can fully recover if transplantation is not required. It is likely that this, in addition to 
ascertainment bias (most study data was reported from transplant centres), accounts for the 
discrepancy between the proportion of those with cirrhosis and those requiring transplantation.  
HCC was not reported in children suggesting it is extremely rare. In adults, the overall incidence 
of 1.3% was similar to published data for aetiologies such as alcohol-related liver cirrhosis and 
primary biliary cholangitis (57).  A slightly higher incidence was recorded in one paper 
investigating patients with AATD, but this study included heterozygotes with concurrent 
hepatitis B and C, and the majority of HCC cases involved subjects with cirrhosis and viral liver 
disease (58). Histological studies have associated cholangiocarcinomas and combined 
hepatocholangiocarcinomas with the PiZZ phenotype, but these were not reported in our follow 
up studies (59, 60).  
Mortality due to AATD related liver disease in both children and adults has significantly 
declined since the late 1980s when liver transplantation became standard practice for end-stage 
liver disease secondary to AATD.  Outcomes following liver transplantation for both paediatric 
and adult studies were excellent and comparable with other common indications for 
transplantation (61). 
 
Limitations of the study.  
Unfortunately heterogeneity of data and risk of bias was such that we were unable to perform a 
meta-analysis.  The majority of studies were retrospective and there was significant selection 
bias; basic demographic data such as age and sex of participants was missing in several studies 
and long-term follow up was often incomplete.  In addition, many of the studies included 
heterozygous and/or non-polymerogenic phenotypes and liver related outcomes for these 
individuals were usually inseparable from those with PiZZ phenotype.  In addition, a number of 
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studies were written by a small number of authors, contributing to the detection, selection and 
attrition bias already discussed and outlined in figures 2 and 3. 
The clinical course of liver disease in individuals with AATD remains poorly understood, but 
approximately 10% of those with deficient phenotypes are likely to experience significant 
morbidity secondary to liver disease at some point during their lifetime. Further prospective 
studies are required to better understand which individuals are prone to develop liver disease 
and the mechanism behind liver injury in these individuals.  Detecting early fibrosis in 
individuals with AATD is currently the best method of identifying those at risk of significant 
liver disease, and non-invasive methods as an alternative to liver biopsy may soon be validated 
in this population.  It is hoped that drugs currently in phase 2 trials will become available in the 
future and can be used to target those with fibrosis, providing a long-awaited treatment 
alternative to liver transplantation.  
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Table 3.   A summary of all included studies for AATD related liver disease in children and adults.  
AATD, alpha-1-antitrypsin deficiency; BA, biliary atresia; CLD, chronic liver disease; HCC, hepatocellular carcinoma; HTN, hypertension; LFTs, liver function disease; LT, liver 
transplantation; M, male; mth, month; pt, patient; wk, week; yr, year 
Author 
and year 
Study design Description  Sample Size Phenotype (%) Sex  (% 
male) 
Mean age 
(range) 
Control/Comparator Primary outcomes Follow up 
PAEDIATRIC STUDIES 
Rujner et al, 1991 
(49) 
Case control 
study 
Case control, comparing 
fibrosis with levels of 
procollagen III 
31 PiZZ – 23 
(74.2%) 
PiMZ – 6 (19.4%) 
PiSS – 1 (3.2%) 
PiFZ – 1 (3.2%) 
  
24 (77.4%) NR Cholestasis vs no cholestasis 
Degrees of fibrosis compared 
No association between collagen III and degree of hepatic fibrosis found 2.5 mths - 14 
yrs 
Moroz et al, 1976 
(44)  
Prospective 
study 
Prospective review of AATD 
cases identified by screening 
those with liver disease 
between 1969 and 1979, 
plus 7 healthy PiZZ siblings 
25 All PiZZ 
 
NR  NR No control  Death – 4 (16%) 
Severe Liver disease – 3 (12.0%)  
Asymptomatic – 11 (44.0%)  
 
 
10 yrs 
Hadchouel et al, 
1976 
(45) 
Prospective 
study 
Prospective follow up of 15 
children with neonatal 
cholestasis diagnosed with 
AATD 
15 All PiZZ 
 
NR  16 mths – 19 
yrs 
No control Jaundiced – 4 (26.7%) 
Not Jaundiced –10 (73.3%) 
Portal HTN – 5 (35.7%) 
Splenomegaly – 3 (21.4%) 
 
 
NR 
Sveger et al, 1976 
(21) 
Prospective 
study 
Prospective follow up of 183 
individuals with AATD (any 
genotype) identified by 
screening 200000 children 
between 1972 and 1974. 6 
month follow up 
176 PiZZ – 125 
(71.0%) 
PiSZ – 48 
(27.2%) 
PiMS – 1 (0.6%) 
PiMZ – 2 (1.2%)  
NR  NR No control  Severe obstructive jaundice – 12 (7.0%)  
Subclinical jaundice – 5 (3.0%)  
2 yrs  
Sveger et al, 1978 
(22) 
 
Prospective 
study 
Prospective follow up of 176 
individuals with AATD (any 
genotype) identified by 
screening 200000 children 
between 1972 and 1974. 2 
year follow up 
176 PiZZ – 125 
(71.0%) 
PiSZ – 48 
(27.3%) 
PiMS – 1 (0.6%) 
PiMZ – 2 (1.1%) 
NR  NR PiMZ, PiSZ and PiMS pts  Cirrhosis – 3 (1.7%) all PiZZ 
Hyperbilirubinamia – 19 (11.0%), all PiZZ  
Liver Disease –10 (6.0%), all PiZZ 
No Liver Disease –146 (83.0%) 
 
2 yrs 
Odievre et al, 
1981 (48) 
 
 
 
Prospective 
study 
Follow up of patients with 
prolonged cholestasis before 
age of 3 months 
103 PiZZ – 17 (100%) Not 
reported for 
AATD 
NR No control  Liver disease – 5 (29.4%) NR 
Sveger et al, 1981 
(23) 
Prospective 
study 
Prospective follow up of 172 
individuals with AATD (any 
genotype) identified by 
screening 200000 children 
between 1972 and 1974. 
Follow up age 4 
183 PiZZ – 126 
(68.9%) 
PiSZ – 53 
(29.0%)  
PiZ- – 2 (1.1%)  
PiS- – 1 (0.5%)  
PiFZ – 1 (0.5%) 
 
NR  AATD 
4.3 yrs (3.9 - 
5) 
 
Control  
4.2 yrs (4.0 - 
4.6) 
80 random controls (not 
screened) 
Death – 1 (0.5%), PiZZ aged 3.7 yrs, aplastic anaemia, cirrhosis at post mortem 
Cirrhosis – 2 (1.1%), both PiZZ 
Neonatal Jaundice – 14 (7.7%), all PiZZ 
Hepatomegaly/deranged LFTs – 1 (0.5%), PiZZ 
 
4 yrs 
Nemeth et al, 
1982 (43) 
Prospective 
study 
Thirteen children aged 4-6 
with PiSZ or PiZZ with no 
history of neonatal 
cholestasis, identified 
through screening, 
prospectively followed up 
13 PiZZ – 8 (61.5%) 
PiSZ – 5 (38.5%) 
 
PiZZ – 7 
(87.5%) 
PiSZ – 4 
(80.0%) 
NR No control Death – 1 (7.7%), GI bleed 
Asymptomatic 12 (92.3%) 
Biospy (N = 7) 
 Cirrhosis – 1 (7.7%), PiZZ phenotype 
 Fibrosis – 4 (30.0%), 1 PiSZ 
NR 
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Nemeth et al, 
1982 (27) 
Prospective 
study 
Ten children with PIZZ and 
neonatal cholestasis 
followed up to ages 4-20 
years 
10 All PiZZ 
 
NR  NR No control Cirrhosis– 3 (30%) 
Portal Hypertension –2 (20%) 
Prolonged Jaundice 2 (20%) 
NR 
Nebbia et al, 1983 
(46) 
Prospective 
study 
Prospective follow up of 45 
children with AATD who had 
been referred with neonatal 
cholestasis; 25 who 
developed cirrhosis before 
the age of 8 compared with 
those who did not 
45 PiZZ – 44 
(97.8%)  
PiMZ – 1 (2.20%) 
25 (56.8%) NR No control Death – 6 (13.3%) 
Cirrhosis – 25 (55.0%) 
 
Jaundice 
 Resolved by 6 mths – 19 (42.2%) 
 Resolved by 88 mths – 2 (4.4%) 
 Progressive liver disease – 6 (13.3% - all died) 
 Portal HTN – 12 (26.6%) 
 
NR 
Sveger et al, 
1984(24) 
Prospective 
study 
Prospective follow up of 176 
individuals with AATD (any 
genotype) identified by 
screening 200000 children 
between 1972 and 1974. 8 
year follow up 
176 PiZZ – 125 
(71.0%) 
PiSZ – 48 
(27.2%) 
PiMS – 1 (0.6%) 
PiMZ – 2 (1.2%) 
NR NR No control  Death – 9 (5.1%) 
Asymptomatic –146 (83.0%) 
 
8 yrs   
Mellado et al, 
1986 (47) 
Prospective 
study 
Review of 14 children with 
AATD, divided into 2 groups 
according to age at diagnosis 
14 PiZZ – 12 
(85.7%)  
PiMZ – 2 (14.3%) 
NR  NR No control No significant difference between biopsies in the 2 groups 23 days – 6 yrs  
Sveger et al, 1988 
(25) 
Prospective 
study 
Prospective follow up of 176 
individuals with AATD (any 
genotype) identified by 
screening 200000 children 
between 1972 and 1974. 12 
year follow up 
185 PiZZ– 127 
(68.6%) 
PiSZ – 54 
(29.2%)  
PiZ- – 2 (1.1%)  
PiS- – 1 (0.5%) 
PiFZ – 1 (0.5%) 
 
NR NR PiMZ and PiMS pts Deaths: 
5 (3.2%), all PiZZ, 3 liver cirrhosis, 1 accidental, 1 anaphylaxis  
1 PiSZ, sudden infant death syndrome 
 
  
12 yrs 
Pittschieler et al, 
1992 (29) 
Prospective 
study 
14 PiSZ children detected by 
screening of all children at 
one centre between 1985-
1989 
 
14 All PiZZ 
  
7 (50.0%) NR No control  No negative outcomes  NR 
Sveger et al, 1995 
(26) 
Prospective 
study 
Prospective follow up of 176 
individuals with AATD (any 
genotype) identified by 
screening 200000 children 
between 1972 and 1974. 18 
year follow up 
185 PiZZ – 127 
(68.6%)  
PiSZ – 54 
(29.2%) 
PiZ – 2 (1.1%)  
PiS – 1 (0.5%)  
PiFZ – 1 (0.5%) 
NR  NR No control  Death – 6 (3.2%), 5 PiZZ and 1 PiSZ 
Raised LFTs – 2 (1.1%)   
 
16 - 18 yrs 
Ghishan et al, 
1988 (9) 
Retrospective 
study 
Retrospective follow up of 
18 patients with PIZZ AATD 
18 All PiZZ  15 (83.3%)  2 mths  No control Death – 2 (11.1%), variceal bleed and histoplasmosis 
Cirrhosis – 3 (16.7%) 
Elevated AST – 18 (100%) 
 
3.7 yrs +/-2.4 
yrs 
Ibarguan et al, 
1990 (28) 
Retrospective 
study  
Retrospective observational 
study of 98 children with 
AATD referred to paediatric 
department between 1967 
and 1988 
98 PiZZ – 95 
(96.9%) 
PiSZ – 3 (3.1%) 
 
54 (55.1%) NR No control Death, N = 25 (25.5%), 9 male (44%), 14 female (56.0%), mean age 5 yrs (range 6 wks 
- 19 yrs) 
Transplanted, N = 26, 16 male , 10 female (38.5%), mean age at transplant, female 8.4 
yrs (range 7 mths - 19 yrs), male 7.8 yrs (range 1-18yrs) 
 Alive – 18 (69.2%)  
 Death – 8 (30.8%), 5 female, 3 male 
Mean 5.3 yrs (1 
mth - 27 yrs) 
Filipponi et al, 
1994 (11) 
Retrospective 
study 
Retrospective review of 
children referred for 
transplant with AATD 
16 All PiZZ 
  
9 (56.3%) NR No control Transplant (N = 16)  
 Hepatosplenomegaly – 16 (100%)  
 Varices – 16 (100%)  
 Jaundice – 9 (56.3%)  
 Ascites – 9 (56.3%)  
 Histological cirrhosis – 16 (100%) 
Neonatal jaundice – 7 (43.8%) 
 
22 mths 
Francavilla et al, 
2000 (30) 
Retrospective 
study  
Retrospective observational 
study of 97 children with 
97 All PiZZ 
  
58 (60.0%) 1.9 mths (1 wk 
to 11.5 yrs) 
No control  Jaundice – 82 (84.5%)  
Transplant – 24 (24.7%) 
Median follow 
up 
21 
 
AATD referred to a 
paediatric transplant unit 
between 1989 and 1998 
 (transplanted) 
3.9 yrs (1-9) 
Prachalias et al, 
2000 (31) 
Retrospective 
study 
A study of 21 patients all 
receiving liver transplant 
due to AATD 
21 All PiZZ 
 
NR  NR No control Transplanted – 21 (100%) 
Clinical features at transplant: 
Portal HTN – 18 (85.7%) 
Jaundice – 16 (76.0%)  
Hepatosplenomegaly – 15 (71.0%)  
Ascites – 14 (67.0%)  
Oesophageal Varices – 9 (42.8%)  
Gastrointestinal bleed – 6 (28.5%)  
Encephalopathy – 1 (9.5%)    
 
 8 yrs 
Hinds et al, 2006 
(33) 
Retrospective 
study  
Retrospective review of 
patients and their siblings 
with PiZZ AATD presenting 
between 1978 and 2002 
235  
Liver 
involvemen
t 74 
 
PIZZ – 58 
(24.7%) 
32 (55.2%) NR No control  Transplant – 7 (12.1%) 
Liver Disease – 21 (72.0%)  
No Liver disease – 8 (29.0%)  
No concordance in liver disease severity between siblings with PiZZ 
 
80 mths (30 -
240) 
Bakula et al, 2007 
(37) 
Retrospective 
study 
Fifty nine children admitted 
for cholestasis/hepatitis, 
homozygous for AATD 
59 All PiZZ  
  
NR  NR No control  Death 3 (5.1%) 
Varices   
 5 yrs –2 (3.4%) 
 8-11 yrs – 9 (15.3%) 
 
From diagnosis 
to LT 4-17 yrs  
No LT 7-14 yrs 
Camarena et al, 
2010 (34) 
Retrospective 
study 
Retrospective review of 
patients presenting in 
infancy or later with liver 
disease and found to have 
AATD 
79 PiZZ – 73 
(92.4%) 
PiSZ – 6 (7.6%)  
 
NR  NR No control Death or Transplant – 35 (44.6%), all had presented with neonatal cholestasis, 34 PiZZ, 
1 PiSZ 
10 – 16 yrs 
Pfister et al, 2011 
(13) 
Retrospective 
study 
Retrospective follow up of 
all PIZZ carriers presenting 
to unit 
53 All PiZZ  
 
NR  NR No control  Death – 8 (15.1%) 
Transplant – 17 (32.1%) 
 
1.5 – 2 yrs 
(transplant 
only) 
Kekez et al, 2015 
(35) 
Retrospective 
study 
Retrospective analysis of 
database of PIZZ children 
diagnosed between 1979 
and 2012 
292 All PiZZ 
 
113 
(38.7%) 
NR No control  Death – 3 (3.5%), all pre transplant era 
Severe disease – 21 (21.9%) 
Moderate Disease – 4 (4.2%) 
Mild Disease – 23 (23.9%)  
Asymptomatic – 6 (6.3%) 
Normal – 42 (43.7%) 
15 yrs   
Lang et al, 2005 
(36) 
Retrospective 
study  
Retrospective analysis of 48 
patients with AATD, 
prevalence of liver disease at 
time of diagnosis 
48 PiZZ – 12 
(25.0%) 
PiMZ – 17 
(35.4%) 
PiMS – 7 (14.5%)  
PiSZ – 2 (4.2%)  
PiVZ – 2 (2.1%)  
PiMP – 2 (2.1%)   
Rare Variants – 8 
(16.7%) 
21 (43.7%) NR No control Death – 2 (4.20%) 
Transplanted – 1 (2.1%) , later died of fungal disease  
Liver disease – 3 (6.3%)  
 
NR  
Pferdmenges et 
al, 2013 (12) 
Retrospective 
study  
Retrospective review of 
patient's files with AATD 
with telephone follow up, 
those with good and poor 
outcomes and compared 
53 All PiZZ 
 
 
Group 1 
(poor 
outcome) 
9 (37.5%) 
0 - 18 yrs Those with good and poor 
outcomes compared 
Asymptomatic – 29 (4.7%)  
Liver disease – 24 (45.3%) 
Transplant – 22 (41.0%) 
Death – 9 (17%), 8 transplanted, 1 died on waiting list 
NR 
Karitzky et al, 
1978 (62) 
Retrospective 
study 
Review of 12 patients with 
PiZZ, five of whom had liver 
disease 
12 All PiZZ NR  NR No control Death – 1 (0.8%) 
 
NR 
ADULT STUDIES 
Bernspang et al 
2009 (38) 
Prospective 
study 
Follow up of a cohort of 
patients with AATD at 30 
years 
129 PiZZ – 89 
(69.0%)   
PiSZ – 40 
(31.0%) 
 
PiZZ – 37 
(41.5%) 
PiSZ – 20 
(50.0%) 
Control – 37 
31 yrs No control All well 
Abnormal LFTs – 6 (5.0%) 
 
 
Aged 30 yrs 
22 
 
(44.0%) 
Tanash et al, 
2015 (15) 
Prospective 
study 
Prospective follow up of 176 
individuals with AATD (any 
genotype) identified by 
screening 200000 children 
between 1972 and 1974. 18 
year follow up 
122 PiZZ – 88 
(72.1%) 
PiSZ – 34 
(27.9%) 
 
NR NR No control  Deranged LFTs – 7 (5.7%) one had Hepatitis C 
All well 
 
 34 yrs 
Triger et al, 1976 
(39) 
Retrospective 
study and case 
series  
Retrospective analysis of 13 
pts aged 16-73 with AATD 
13 PiZZ – 9 (69.2%) 
PiMZ – 2 (15.4%)  
Unknown – 2 
(15.4%) 
 
 
7 (53.8%) Presentation 
48.2 yrs (4 
mths - 73 yrs) 
 
Follow 
up/death 
52.8 yrs (16 - 
74) 
No control  Death – 7 (53.8%), 1 respiratory failure, 3 hepatic coma (two with alcohol excess), 2 
varices, 1 hepatic rupture) 
Alive – 6 (46.2%) 
 
1 mth - 26 yrs  
Rakela et al, 1987 
(40) 
Retrospective 
study 
Review of electronic records 
of 19 adult patients with 
AATD and liver disease 
19 PiMZ – 8 (42.1%)  
PiZZ – 9 (42.1%) 
PiSZ – 3 (15.8%) 
 
Total 13 
(68.4%) 
PiZZ – 7 
(87.5%) 
PiSZ – 1 
(33.3%) 
PiMZ – 5 
(62.5%) 
NR No control Death – 8 (42.1%) NR 
Propst et al, 1995 
(41) 
Retrospective 
study 
Review of 6890 patients 
referred to gastroenterology 
tertiary centre between 
1978 and 1993. Those with 
CLD compared with those 
that did not develop CLD 
160 
Grp 1: 54 
Grp 2: 106 
Grp 1 (CLD) 
PiZZ – 3 (6%)  
PiMZ – 42 (78%) 
PiFZ – 5 (9%) 
PiSZ – 4 (7%) 
 
Grp 2 (No CLD)  
PiMZ – 94 (88%) 
PiFZ – 2 (2%) 
PiZZ – 4 (4%)  
PiSZ – 6 (6%) 
 
Grp 1 – 34 
(63.0%) 
Grp 2 – 64 
(59.3%) 
CLD 
55.7 yrs 
 
 
 
No CLD 
50.4 yrs 
Those with signs of CLD 
compared with those without 
Group 1 outcome only (CLD): 
Death – 4 (8.0%) 
Cirrhosis – 32 (59.2% - Child Pugh A 34%, B 39%, C 27%) 
HCC – 6 (11.1%) 
Chronic hepatitis –22 (40.7%) 
NR  
Volpert et al, 
2000 (14) 
Retrospective 
study 
All patients known to have 
AATD taken from a database 
of patients with abnormal 
liver biochemistry results 
44 All PIZZ 
 
25 (56.8%) 16-73 yrs No control  Death – 1 (2.3%) 
Cirrhosis or Portal HTN – 17 (38.6%) 
Liver Transplant – 5 (11.4%)   
Lost to follow up – 2 (4.5%) 
 
1 mth – 26 yrs 
Bowlus et al, 
2005 (42) 
Retrospective 
study 
Retrospective study of 
patients who self-reported 
having AATD 
139 PiZZ – 99 
(71.3%) 
PiMZ – 25 
(18.0%)  
Unknown 14 
(10.70%) 
(Self-reported) 
 
NR 43.5 yrs (1-75 
yrs) 
No control Liver transplant – 41 (29.5%)  NR 
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Table 4. All included studies for transplant in AATD in children and adults 
Author 
and year 
Study design Description  Characteristics of treated group Treatment Control/Comparator Indications for transplant/clinical 
features at transplantation 
 
Survival – patient/graft Duration of follow up 
Filipponi et al, 1994 (11) Retrospective 
review 
Retrospective review 
of children with 
AATD  referred for 
liver  transplantation 
N = 16 
Phenotype: PiZZ – 16 
Gender: M – 9 (56.3%) 
LT No control Varices – 16 (100%),  
Ascites – 9 (56.3%), Encephalopathy – 0 
(0%). 
15 patients (94%) were alive after a 
median follow-up of 22 mths. 
2 required regraft 
22 mths 
Francavilla et al, 2000 
(30) 
Retrospective 
observational  
Retrospective 
observational study 
of 97 children with 
AATD referred to a 
paediatric transplant 
unit between 1989 
and 1998 
N = 26 
Phenotype: PiZZ – 26 
Gender: not reported for treated group 
Median age at referral: NH group 1.9 mths 
(range 1 wk to 11.5 yrs), Chronic liver disease 
group 11.3 mths, range (4.8 to 11.5 yrs) 
Ethnicity: Caucasian N = 26 
LT Divided into neonatal 
hepatitis (NH) 
transplanted and  (LT) 
non-transplanted, and 
chronic liver disease 
(CLD) transplant and 
non-transplant 
Recurrent ascites – 19 (79%),  
Coagulopathy – 15 (61%), 
Recurrent jaundice – 12 (50%). 
Pt survival, 1 year: 96%, 5 yr 92%, 
Graft survival at 1 and 5 yrs 79% 
2 deaths. One at 3 mths (intracranial 
haemorrhage), one at 3 yrs (sepsis)  
Survival data unavailable for control 
group. 
One patient received 2 grafts and 1 
received 3 grafts. 
Median follow up (transplanted) 3.9 
yrs (1-9 yrs)  
Hughes et al, 2011 
(50) 
Retrospective 
observational 
Retrospective review 
of LT in recipients 
with AATD compared 
with those with 
biliary atresia (BA) 
N = 35 
Phenotype: PiZZ –  34, PiSZ –  1 
Median age at transplantation: 6 yrs (1-10) 
Gender: M –20 (57.1%) 
LT Patients with BA Ascites – 24 (69.0%),  
Bacterial peritonitis – 7 (20.7%),  
GI bleeding – 13 (37.5%), Encephalopathy 
– 8 (24.1%). 
Pt survival AATD: 1 yr 82.7%, 5 yr 
76.5%, 10 yr 76.5% 
Graft survival 1 yr 68.4%, 5 yr 68.4%, 
10 yr 68.4% 
Pt survival BA: 1 yr 70.0%, 5 yr 60.3%, 
10 yr 55.9% 
Graft survival BA: 1 yr 66.2%, 5 yr 
55.8%, 10 yr 52.5% 
>10 yrs in 50%  
Prachalias et al, 2000 (31) Retrospective 
observational 
A study of 21 patients 
all receiving liver 
transplant due to 
AATD 
N = 21 
Phenotype: PiZZ – 21 
Gender: not reported  
Age at diagnosis: <6 mths in 1, >5 yrs in 2 
children.  
LT No control Jaundice (BR > 20 ymol/l) –  16 (76.1%) 
Ascites – 14 (66.6%)  
Oesophageal varices – 9 (42.8%), 
Encephalopathy – 1 (9.5%).  
21 children are alive at a median 
follow-up of 40 mths (range 3-97 mths).  
4 pts underwent a re-transplant.. The 
indication for re-transplantation was 
hepatic artery thrombosis N = 3, 
chronic rejection N = 1 (well 8 yrs post-
transplant). 
Median 40 mths 
Migliazza et al, 2000 (51) Retrospective  Review of 198 
children undergoing 
LT at a single centre 
Sixteen patients with AATD 
No other demographics reported 
LT No control Not reported Outcomes for pts with AATD not 
defined.  
All Pt survival: 1 yr 80%, 3 yrs 76%, 5 
yrs 74%, 10 yrs 74%.  
Graft survival at 1 yr 63%, 3 yrs 60%, 5 
yrs 58%, 10 yrs 58%. 
Median 41 mths (0 to 154 mths) 
Bakula et al, 2007 (37) Retrospective Fifty nine children 
admitted for 
cholestasis/hepatitis, 
homozygous for 
AATD 
N = 59 
Treated N = 11 (LT) 
Phenotype: PiZZ – 59  
Gender: not reported  
Age: range 10.3-17.1 yrs 
LT No control  Not reported Transplant outcomes not reported.  From diagnosis to LT 4-17 yrs  
No LT 7-14 yrs 
Carey et al, 2013 (52) Retrospective Review of pts 
undergoing LT for 
AATD across three 
transplant centres 
N = 123 
Phenotype: PiZZ – 50, PiSZ – 23 
Control PiMZ – 50  
Gender: M PiSZ – 18 (78.3%), PiZZ – 38 
(76.0%), PiMZ – 37 (74.0%). 
Age at LT: PiSZ – 53.0 yrs (28-69), PiZZ –47.8 
(1-69), PiMZ – 57.7 (30-70) 
Ethnicity: not reported 
 
*includes paediatric pts  
LT 
 
PiMZ – 50 
Transplanted for other 
indications 
Not reported PiZZ group: 1yr 94%, 3 yrs 92%, 5 yrs 
92%, 10 yrs 86%.  
PiSZ group: 1 yr 86%, 3 yrs 83%, 5 yrs 
80%, 10 yrs 72% 
MZ control group: 1 yr 91%, 3 yrs 86%, 
5 yrs 79%, and 10 yrs 79%.  
23 pts died during the follow-up period.   
1 pt in the ZZ and SZ grps died of 
pulmonary complications.  
No pts required regraft 
 
Up to 25 yrs 
Esquivel et al, 1987 (53) Retrospective Single centre 
experience of all 
patients transplanted 
for AATD between 
1980 and 1986 
N = 39 
Paediatric N = 29  
Mean age at LT: 5 yrs (0.66-13) 
Phenotype: PiZZ – 22 (76.0%), PiSZ – 2 (7.0%), 
PiMZ – 3 (7.0%), unknown – 3 (10.0%) 
LT No control  Paediatrics: Ascites 23 (79.0%), GI 
bleeding 17 (59.0%), Jaundice 11 (38.0%), 
Encephalopathy 3 (10.0%). 
Adults: 
Ascites – 8 (80.0%)  
Paediatrics 
5 yr survival: 83% 
3 patients required regraft 
All survivors are attending school 
 
Paediatric: mean 26 mths (8 to 60) 
24 
 
 
Adults N = 10  
Median age: 34 yrs (18-48) 
Phenotype: PiZZ – 8 (80.0%), PiMZ – 2(20.0%)    
 
Jaundice – 2 (20.0%)  
Encephalopathy – 4 (40.0%) 
Adults 
5 yr survival 60% 
2 adults required regraft 
 
Kemmer et al, 2008 (54) Retrospective Review of LT for 
AATD from the UNOS 
database 
567 LT recipients for AATD 
 
Children N = 161  
Gender: M – 98 (60.9%) 
Median age: 3 yrs (0.5-17) 
Ethnicity: White – 144 (89.4%), Hispanic – 10 
(6.2%), other – 7 (4.4%) 
Adults N = 406  
Gender: M – 294 (72.4%) 
Median age: 52 yrs (18-70) 
Ethnicity: White – 396 (97.5%), Hispanic – 6 
(1.5%), other – 4 (1%)    
Phenotypes: not reported 
LT No control Not reported Pt survival paediatrics: 1 yr 84%, 3 yrs 
81%, 5 yrs 78%. 
Pt survival adults: 1 yr 83%, 3 yrs 79%, 
5 yrs 77%.  
Up to 9 yrs 
Kilpe et al, 2003 (55) Retrospective Review of LT data 
from 37 centres 
5180 cases reviewed 
N = 116 with AATD 
Age 0-14 N =12 
Age ≥14 yrs, n=104 
LT Compared with other 
indications for 
transplantation 
Not reported Outcomes for AATD not given 
separately 
Up to 9 yrs 
Vennarecci et al, 1996 
(56) 
Retrospective All pts referred for LT 
for AATD, single 
centre 
N = 81 total 
Transplanted grp 
Children N = 13  
Gender: M – 11 (84.6%) 
Median age: 4.6 yrs (0.4-11.9 yrs)  
All PiZZ 
All British born, ethnicity not specified 
 
Adults N = 22 
Gender: M – 19 (86.4%) 
Median age: 44 yrs (16-68.8 yrs) 
Phenotypes: PiZZ – 3 (13.6%), PiSZ – 1 (4.5%), 
PiMZ – 9 (40.9%), PiMM – 3 (13.6), PiMS – 2 
(9.1%), not recorded 4 (18.2%) 
LT Those referred and 
not transplanted  
Not reported Paediatric 
Survival (overall): 1yr 69%, 
transplanted after 1990 87.5% 
2 pts re-transplanted because of 
chronic rejection.  
Five children died of the following: 
cardiac arrest of uncertain cause, 
fulminant rejection in an ABO-
incompatible donor LT, chronic 
rejection (2), and left ventricular failure 
secondary to myocarditis. 
 
Adults 
Survival (overall 60%, transplanted 
after 1990, 73%. 
Two patients were re-transplanted for 
hepatic artery thrombosis and ischemic 
graft failure. Seven patients died of the 
following: cardiac arrest, pneumonia 
(3), haemorrhage from hepatic artery 
anastomosis dehiscence, primary non-
function, and myocardial infarct. 
 
Median 48 mths (8 -114 mths) 
Bowlus et al 2005 (42) Retrospective Retrospective review 
of self-reported 
outcomes in a cohort 
of patients with 
AATD 
Children N = 15 
Gender: M – 8 (53.3%) 
Mean age at transplantation (diagnosed in 
childhood): 16.9 ± 21.7 yrs 
Phenotype: PiZZ – 13 (86.7%), other 2 (13.3%) 
Ethnicity: White – 13 (86.7%), non-white – 2 
(13.3%) 
 
Adults N = 25 
Gender: M - 20 (80%) 
Mean age at transplantation: 51.6 ± 8.3 yrs 
Phenotype: PiZZ – 16 (64.0%), other 9 (36.0%) 
Ethnicity: white – 23 (92.0%), non-white – 2 
(8.0%) 
 
LT No control Indication not reported Transplant - 41 (29.5%) were 
transplant recipients or on waiting list – 
outcomes not reported 
Not reported 
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Table 5. A summary of biopsy findings from included studies. 
Author 
and year 
Study design Description  Sample Size Phenotype (%) Biopsy Findings 
Children 
Hadchouel et al, 
1976 (45) 
 
Prospective 
study 
Prospective follow up of 15 children with 
neonatal cholestasis diagnosed with AATD 
15 All PiZZ 
 
Performed at 1 - 6 mths  
PAS +ve globules present in all pts 
Pts were divided into 3 groups:  
G1, n=6, cholestasis, hepatocellular damage, mild portal fibrosis; improvement in liver injury seen  
G2, n=5, significant portal fibrosis and bile duct proliferation; all developed cirrhosis,  
G3, n=4, ductular hypoplasia; suffered prolonged cholestasis 
Odieve et al, 1976 
(48) 
 
Retrospective  
study 
Retrospective analysis of 424 children screened 
for AATD over 3.5 years 
36 PiZZ – 19 (52.8%)  
PiMS – 7 (19.4%) 
PiMZ – 6 (16.7%) 
PiSZ – 4 (11.4%) 
 
4 biopsies performed in PiZZ pts aged between 2 mths and 6.5 yrs  
Features: PAS +ve granules, absent intrahepatic bile ducts in all 
Mixed genotype - no intracellular PAS positive deposits (+ve in all PiZZ) 
 
Nemeth et al, 1982 
(43) 
Prospective 
study 
Thirteen children aged 4-6 with PiSZ or PiZZ 
with no history of neonatal cholestasis, 
identified through screening, prospectively 
followed up 
13 PiZZ – 8 (61.5%) 
PiSZ – 5 (38.5%) 
 
Features at diagnosis 
Cirrhosis  – 1 
Fibrosis  – 5 
Steatosis  – 5 
Nuclear vacuolisation  – 2 
Normal  – 1 
 
Nemeth, 1982 (27) Prospective 
study 
Ten children with PIZZ and neonatal cholestasis 
followed up to ages 4-20 years 
10 All PiZZ 
 
Performed ages 4-20 
Cirrhosis  – 3  
Fibrosis  – 1  
Normal  – 2 
poor biopsy  – 1  
not done  – 1  
 
Nebbia et al, 1983 
(46) 
Prospective 
study 
Prospective follow up of 45 children with AATD 
who had been referred with neonatal 
cholestasis; 25 who developed cirrhosis before 
the age of 8 compared with those who did not 
45 PiZZ – 44 (97.8%)  
PiMZ – 1 (2.20%) 
Grp 1, cirrhosis, n=25 infancy 
Grp 2, no cirrhosis, n=20 
Ghishan et al, 1988 
(9) 
Retrospective 
study 
Retrospective follow up of 18 pts with PIZZ 
AATD 
18 All PiZZ  Performed at presentation in 14 
Cirrhosis – 3 
Portal fibrosis – 1 
Bridging fibrosis – 3 
Mild fibrosis – 1 
Cholestasis – 13 
Neonatal hepatitis – 7 
Decreased bile ducts – 1  
Rujner et al, 
1991(49) 
Case control 
study 
Case control, comparing fibrosis with levels of 
procollagen III 
31 PiZZ – 23 (74.2%) 
PiMZ -6 (19.4%) 
PiSS – 1 (3.2%) 
PiFZ – 1 (3.2%) 
  
No correlation was found between the degree liver fibrosis determined by histological examination and the serum concentration of 
procollagen type III peptide 
Pittschieler et al, 
1992 (29) 
Prospective 
study 
14 children with PiSZ detected by screening of 
all children at one centre between 1985 and 
1989, prospectively followed up 
14 All PiZZ 
  
Performed in 1 pt - normal 
Filipponi et al, 1994 
(11) 
Retrospective 
study 
Retrospective review of children referred for 
transplant with AATD 
16 All PiZZ 
  
Performed at diagnosis 
PAS positive diastase-resistant cellular inclusions  – 11  
Cirrhosis – 6 
Extensive portal fibrosis with ductular proliferation – 5 
Mild portal fibrosis – 3 
Paucity of IL bile ducts – 2 
Francavilla et al, 
2000 (30) 
Retrospective 
study  
Retrospective observational study of 97 children 
with AATD referred to a paediatric transplant 
unit between 1989 and 1998 
97 All PiZZ 
  
Median age at biopsy 1.8 mths (range 2 wks-16 mths)  
Group with neonatal hepatitis requiring transplantation (NH,LT): cirrhosis 4, bridging septa 6, cholestasis 11, bile duct 
reduplification 9, PAS granules 3, bile duct hypoplasia 2, portal inflammation 2  
Neonatal hepatitis, no liver transplant (NH,no LT): cirrhosis – 2, bridging septa – 5, cholestasis – 32, bile duct reduplification – 8, 
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PAS granules – 10, bile duct hypoplasia– 6, portal inflammation – 5. (Significantly more cirrhosis, bridging septa, severe fibrosis, bile 
duct reduplification compared to those without TP).  
Group with chronic liver disease (CLD, LT) requiring transplantation: cirrhosis – 3, bridging septa – 2, PAS granules– 5, portal 
inflammation – 2,  
CLD and no liver transplant (CLD, no LT): cirrhosis – 1, bridging septa – 2, PAS granules – 4, portal inflammation – 1. 
 
Follow up biopsy after a median 6.3 mths in TP group (n=18) and 26 mths non-TP group (n=38).  
NH,LT: cirrhosis – 11, bridging septa – 15, cholestasis – 6, bile duct reduplification – 10, PAS granules – 9, portal inflammation – 9,  
NH,no LT: cirrhosis – 3, bridging septa – 11, cholestasis – 2, bile duct reduplification – 4, PAS granules – 21, portal inflammation – 3. 
(Significantly more cirrhosis, bridging septa, severe fibrosis, bile duct reduplification compared to those without TP).  
CLD, LT: cirrhosis – 3, PAS granules – 3, portal inflammation – 2, CLD  
CLD, no LT=cirrhosis – 1, PAS granules – 2, portal inflammation– 0 
 
Camarena et al, 2010 
(34) 
Retrospective 
study 
Retrospective review of patients presenting in 
infancy or later with liver disease and found to 
have AATD   
 
79 PiZZ – 73 (92.4%) 
PiSZ – 6 (7.60%)  
 
N=30, all of whom had neonatal cholestasis: ductopenia – 8, ductal proliferation – 6, giant cells – 6, nonspecific cholestasis/fibrosis – 
13. 
Mellado et al, 1986 
(47) 
Prospective 
study 
Review of 14 children with AATD, divided into 2 
groups according to age at diagnosis 
14 PiZZ – 12 (85.7%)  
PiMZ – 2 (14.3%) 
Considerable histological variation between pts, no consistent pattern seen. 
Adult      
Triger et al, 1976 
(39) 
Retrospective 
study and case 
series  
Retrospective analysis of 13 patients aged 16-73 
with AATD  
13 PiZZ – 9 (69.2%) 
PiMZ – 2 (15.4%)  
Unknown – 2 (15.4%) 
 
 
Cirrhosis – 8 (macronodular – 7, micronodular – 1), bile duct proliferation present in cirrhotics. 
Fibrosis with enlarging portal tracts – 5  
Piecemeal necrosis – 5  
Hepatoma – 1  
All PiZZ: PAS positive globules and diastase resistant globules.  
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Appendix. Table 6. Bias assessment for all included studies for disease progression in AATD 
Author 
and year 
Study design Description  Sample Size Control/Comparator Bias 
 
Rujner et al, 1991 (49) Case control study Case control, comparing degrees of fibrosis with levels of procollagen III 31 No control  High 
Moroz et al, 1976 (44) Prospective study Prospective review of cases diagnosed with AATD from screening of those with liver disease between 1969 and 1979, plus 7 healthy 
siblings that were tested 
25 No control  High 
Hadchouel et al, 1976 (45) Prospective study Follow up of 15 children diagnosed with neonatal cholestasis and AATD 15 No control High 
Sveger et al, 1976 (21) Prospective study Results of 200000 children screened for AATD between 1972 and 1974. 183 found to have AATD  176 No control  Moderate 
Sveger et al, 1978 (22) 
 
Prospective study 176 children with AATD (any genotype) identified from screening 200000 infants between 1972 and 1974 and prospectively followed 
up 
176 PiMZ, PiSZ and PiMS 
pts  
Moderate 
Odievre et al, 1981 (48) Prospective study Follow up of patients with prolonged cholestasis before age of 3 months 102 No control  High 
Sveger et al, 1981 (23) Prospective study Results of 200000 children screened for AATD between 1972 and 1974. 183 were found to have AATD at examination aged 4 years 183 80 random controls 
(not screened) 
Moderate 
Nemeth et al, 1982 (43) Prospective study Thirteen children aged 4-6 examined either with PiSZ or PiZZ who had not had neonatal cholestasis, 10 through screening, one presented 
later. These 10 children were checked regularly from birth 
13 No control High 
Nemeth 1982 (27) Prospective study Ten children with PIZZ and neonatal cholestasis were followed up to ages 4-20 years 10 No control High 
Nebbia et al, 1983 (46) Prospective study Prospective follow up of 45 children found to have AATD, who had been referred with neonatal cholestasis – 12/25 in first week of life 
and before 8th week of life in the other participants 
45 No control High 
Sveger et al, 1984 (24) Prospective study Results of 200000 children screened for AATD between 1972 and 1974. 183 found to have AATD at 8 year follow up 176 No control  Moderate 
Mellado et al, 1986 (47) Prospective study Review of 14 children with AATD and their biopsies, divided into 2 groups according to when they were diagnosed 14 No control High 
Sveger et al, 1988 (25) Prospective study Results of 200000 children screened for AATD between 1972 and 1974 – follow up aged 12  185 PiMZ and PiMS pts Moderate 
Pittschieler et al, 1992 (29) Prospective study Fourteen PiSZ children detected by screening of all children at one centre between 1985-1989 with follow up 14 No control  High 
Sveger et al 1995 (26) Prospective study Results of 200000 children screened for AATD between 1972 and 1974. There were 183 patients found to have AATD with 16 and 18 
year follow up 
185 No control  Moderate 
Ghishan et al, 1988 (9) Retrospective study Retrospective follow up of 18 pts with PIZZ AATD 18 No control High 
Ibarguan et al, 1990 (28) Retrospective study  Retrospective observational study of 98 children with AATD referred to paediatric department between 1967 and 1988 98 No control High 
Filipponi et al, 1994 (11) Retrospective study Retrospective review of children referred for transplant with AATD 16 No control High 
Francavilla et al, 2000 (30) Retrospective study  Retrospective observational study of 97 children with AATD referred to paediatric transplant unit between 1989 and 1998 97 No control  High 
Prachalias et al, 2000 (31) Retrospective study A study of 21 patients all receiving liver transplant due to AATD 21 No control High 
Hadzic et al, 2005 (32) Retrospective study  Retrospective review of children with PiSZ and PiSS AATD referred to a tertiary service between 1988 and 2002 17 No control  High 
Hinds et al, 2006 (33) Retrospective study  Retrospective review of patients and their siblings with PiZZ AATD presenting between 1978 and 2002 235  
Liver involvement 74,PiZZ 
58 
No control  High 
Bakula et al, 2007 (37) Retrospective study Fifty nine children admitted for cholestasis/hepatitis homozygous for AATD 59 No control  High 
Camarena et al, 2010 (34) Retrospective study Retrospective review of patients presenting in infancy or later with liver disease found to have AATD  79 No control High 
Pfister et al, 2011 (13) Retrospective study Retrospective follow up of all PIZZ carriers presenting to unit 53 No control  High 
Kekez et al, 2015 (35) Retrospective study Retrospective analysis of database of PIZZ children diagnosed between 1979 and 2012 292 No control  High 
Lang et al, 2005 (36) Retrospective study  Retrospective analysis of 48 patients with AATD, prevalence of liver disease at time of diagnosis 48 No control High 
Pferdmenges et al,  2013 
(12) 
Retrospective study  Retrospective review of patient's files with AATD and telephone follow up, divided into good and poor outcomes and compared 53 No control  High 
Karitzky et al, 1978 (62) Retrospective study Review of 12 patients with PiZZ, five of whom had liver disease 12 No control High 
Bernspang et al, 2009 (38) Prospective study Follow up of cohort of patients with AATD at 30 years, with blood tests 129 No control Moderate 
Tanash et al, 2015 (15) Prospective study Results of 200000 children screened for AATD between 1972 and 1974, looking at quality of life, smoking habit and lung and liver 
function of patients at 34 years old 
122 No control  Moderate 
ADULT 
Triger et al, 1976 (39) 
 
 
Retrospective study 
and case series  
 
Retrospective analysis of 13 patients aged 16-73 from 12 families with AATD. Follow up time between 1 month and 26 years  
 
13 
 
No control  
 
High 
Rakela et al, 1987 (40) Retrospective study Review of electronic records of 19 adult patients with AATD and liver disease 19 No control High 
Propstj et al, 1995 (41) Retrospective study Review of 6890 patients referred to gastroenterology tertiary centre between 1978 and 1993 160 
Group 1 – 54 
Group 2 - 106 
AATD but no CLD High 
Volpert et al, 2000 (14) Retrospective study All patients known to have AATD taken from a database of patients with abnormal liver biochemistry results  44 No control  High 
Bowlus et al, 2005 (42) Retrospective study Retrospective study of patients who self-reported having AATD  139 No control High 
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